Drug Profile


Alternative Names: Arxxant; LY 333531

Latest Information Update: 15 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Takeda
  • Class Eye disorder therapies; Indoles; Maleimides
  • Mechanism of Action Protein kinase C beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic macular oedema; Diabetic nephropathies; Diabetic neuropathies; Diabetic retinopathy; Heart failure

Most Recent Events

  • 09 Jun 2016 Children's Hospital Medical Center and The Christ Hospital plan a phase I/II trial for Heart failure in USA (PO) (NCT02769611)
  • 08 Apr 2011 Novartis completes acquisition of Alcon
  • 26 Aug 2010 Alcon has been acquired by Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top